Effects of control interventions on Clostridium difficile infection in England: an observational study

Kate E. Dingle(John Radcliffe Hospital), Xavier Didelot(Public Health England), T. Phuong Quan(John Radcliffe Hospital), David W. Eyre(John Radcliffe Hospital), Nicole Stoesser(John Radcliffe Hospital), Tanya Golubchik(John Radcliffe Hospital), Rosalind M. Harding(John Radcliffe Hospital), Daniel J. Wilson(Centre for Human Genetics), David Griffiths(John Radcliffe Hospital), Alison Vaughan(John Radcliffe Hospital), John Finney(John Radcliffe Hospital), David Wyllie(John Radcliffe Hospital), Sarah Oakley(Oxford University Hospitals NHS Trust), Warren N. Fawley(Leeds General Infirmary), Jane Freeman(Leeds General Infirmary), K. Morris(Leeds General Infirmary), Jessica Martin(Leeds General Infirmary), Philip Howard(Leeds Teaching Hospitals NHS Trust), Sherwood L. Gorbach(Tufts University), Ellie J. C. Goldstein, Diane M. Citron, Susan Hopkins(Royal Free London NHS Foundation Trust), Russell Hope(Public Health England), Alan P. Johnson(Public Health England), Mark H. Wilcox(Leeds General Infirmary), Tim Peto(John Radcliffe Hospital), A. Sarah Walker(John Radcliffe Hospital), Derrick W. Crook(John Radcliffe Hospital), Carlos del Ojo Elías, Charles Crichton, Vasiliki Kostiou, Adam Giess, Jim Davies
The Lancet Infectious Diseases
January 24, 2017
Cited by 319Open Access
Full Text

Abstract

BACKGROUND: The control of Clostridium difficile infections is an international clinical challenge. The incidence of C difficile in England declined by roughly 80% after 2006, following the implementation of national control policies; we tested two hypotheses to investigate their role in this decline. First, if C difficile infection declines in England were driven by reductions in use of particular antibiotics, then incidence of C difficile infections caused by resistant isolates should decline faster than that caused by susceptible isolates across multiple genotypes. Second, if C difficile infection declines were driven by improvements in hospital infection control, then transmitted (secondary) cases should decline regardless of susceptibility. METHODS: Regional (Oxfordshire and Leeds, UK) and national data for the incidence of C difficile infections and antimicrobial prescribing data (1998-2014) were combined with whole genome sequences from 4045 national and international C difficile isolates. Genotype (multilocus sequence type) and fluoroquinolone susceptibility were determined from whole genome sequences. The incidence of C difficile infections caused by fluoroquinolone-resistant and fluoroquinolone-susceptible isolates was estimated with negative-binomial regression, overall and per genotype. Selection and transmission were investigated with phylogenetic analyses. FINDINGS: National fluoroquinolone and cephalosporin prescribing correlated highly with incidence of C difficile infections (cross-correlations >0·88), by contrast with total antibiotic prescribing (cross-correlations <0·59). Regionally, C difficile decline was driven by elimination of fluoroquinolone-resistant isolates (approximately 67% of Oxfordshire infections in September, 2006, falling to approximately 3% in February, 2013; annual incidence rate ratio 0·52, 95% CI 0·48-0·56 vs fluoroquinolone-susceptible isolates: 1·02, 0·97-1·08). C difficile infections caused by fluoroquinolone-resistant isolates declined in four distinct genotypes (p<0·01). The regions of phylogenies containing fluoroquinolone-resistant isolates were short-branched and geographically structured, consistent with selection and rapid transmission. The importance of fluoroquinolone restriction over infection control was shown by significant declines in inferred secondary (transmitted) cases caused by fluoroquinolone-resistant isolates with or without hospital contact (p<0·0001) versus no change in either group of cases caused by fluoroquinolone-susceptible isolates (p>0·2). INTERPRETATION: Restricting fluoroquinolone prescribing appears to explain the decline in incidence of C difficile infections, above other measures, in Oxfordshire and Leeds, England. Antimicrobial stewardship should be a central component of C difficile infection control programmes. FUNDING: UK Clinical Research Collaboration (Medical Research Council, Wellcome Trust, National Institute for Health Research); NIHR Oxford Biomedical Research Centre; NIHR Health Protection Research Unit on Healthcare Associated Infection and Antimicrobial Resistance (Oxford University in partnership with Public Health England [PHE]), and on Modelling Methodology (Imperial College, London in partnership with PHE); and the Health Innovation Challenge Fund.


Related Papers

No related papers found

Powered by citation graph analysis